Mutations of TP53 do not correlate with the sensitivity to paclitaxel - A study using 27 gynaecological cancer cell lines

European Journal of Cancer

Volumn 38, Issue 13, 2002, Pages 1783-1791

  Rantanen, V ^a,b   Engblom, P ^b   Raitanen, M ^b   Hietanen, S ^b,c   Haarala, M ^b   Grenman S ^b   Syrjanen S ^c,d  

^a TURKU CITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Gynaecological cancer cell lines; HPV; Paclitaxel sensitivity; TP53

Indexed keywords

PACLITAXEL; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CELL CULTURE; CELL TRANSFORMATION; CELL TYPE; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; ENDOMETRIUM; ENDOMETRIUM CELL; EVALUATION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VULVA CARCINOMA; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; FEMALE; FEMALE GENITAL TRACT TUMOR; GENETICS; METHODOLOGY; MUTATION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; VIROLOGY; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENES, P53; GENITAL NEOPLASMS, FEMALE; HUMAN; INHIBITORY CONCENTRATION 50; MUTATION; PACLITAXEL; PAPOVAVIRIDAE INFECTIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR CELLS, CULTURED; TUMOR VIRUS INFECTIONS; HUMANS; PAPILLOMAVIRUS INFECTIONS;

EID: 0036024593     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00119-3     Document Type: Article

References (55)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
3. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study
4. New approaches to understanding p53 gene tumor mutation spectra
5. Strategies for manipulating the p53 pathway in the treatment of human cancer
6. Apoptosis in cancer therapy: Crossing the threshold
7. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
8. Mutant p53 protein expression interferes with p53-independent apoptotic pathways
9. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
10. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma
11. P53 and chemosensitivity
12. P53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel
13. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment
14. Are human papillomavirus infections not necessary or sufficient causal factors for invasive cancer of the cervix?
15. Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR
16. Human papillomavirus and the pathogenesis of vulvar carcinoma
17. Intraepithelial neoplasia of the vulva
18. Carcinoma of the vulva: HPV and p53 mutations
19. The p53 tumor suppressor gene frequently is altered in gynecologic cancer
20. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erb-2) and p53 in proliferative, hyperplastic, and malignant endometrium
21. P53 accumulation in ovarian carcinomas and its prognostic implications
22. P53 mutations in epithelial ovarian cancers: Possible role in predicting chemoresistance
23. P53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines
24. Human papillomavirus in vulvar and vaginal carcinoma cell lines
25. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells
26. Endometrial cancer cell lines are sensitive to paclitaxel in vitro
27. Taxane sensitivity of ovarian carcinoma in vitro
28. Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel in vitro
29. Consistent chromosome abnormalities in squamous cell carcinoma of the vulva
30. Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines
31. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines
32. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution
33. A simple salting out procedure for extracting DNA from human nucleated cells
34. A variation in the structure of the protein-coding region of the human p53 gene
35. Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem™
36. Use of polymerase chain reaction amplification for the detection of genital papillomaviruses
37. Analysis of the p53 gene in human uterine carcinoma cell lines
38. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines
39. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines
40. P53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines
41. Taxol binds to polymerized tubulin in vitro
42. Molecular effects of paclitaxel: Myths and reality (a critical review)
43. P53, the cellular gatekeeper for growth and division
44. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
45. Loss of normal p53 function confers sensitisation to Taxol by increasing G2/M arrest and apoptosis
46. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis
47. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells
48. 2/M checkpoint abrogators or altering the p53 status
49. Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel
50. Sensitivity paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells
51. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway
52. P53 mutations in human cancers
53. Activation of p53 in cervical carcinoma cells by small molecyles
54. P53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
55. P53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma